Inventiva S.A. (IVA)
NASDAQ: IVA · IEX Real-Time Price · USD
3.670
+0.150 (4.26%)
May 31, 2024, 4:00 PM EDT - Market closed
Inventiva Revenue
In the year 2023, Inventiva had annual revenue of $25.74M with 28.59% growth.
Revenue (ttm)
$25.74M
Revenue Growth
+28.59%
P/S Ratio
7.47
Revenue / Employee
$214,472
Employees
120
Market Cap
192.20M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 25.74M | 5.72M | 28.59% |
Dec 31, 2022 | 20.01M | 10.35M | 107.19% |
Dec 31, 2021 | 9.66M | 3.24M | 50.51% |
Dec 31, 2020 | 6.42M | -6.27M | -49.41% |
Dec 31, 2019 | 12.69M | 4.20M | 49.58% |
Dec 31, 2018 | 8.48M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
High Tide | 497.66M |
Puma Biotechnology | 226.63M |
Outset Medical | 125.08M |
Fennec Pharmaceuticals | 44.95M |
Cellectis | 12.13M |
Lineage Cell Therapeutics | 8.00M |
Profound Medical | 5.33M |
Delcath Systems | 4.61M |
IVA News
- 3 days ago - Combined General Meeting of June 20, 2024 - Availability of the preparatory documents - GlobeNewsWire
- 11 days ago - Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024 - GlobeNewsWire
- 12 days ago - Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update - GlobeNewsWire
- 17 days ago - Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH - GlobeNewsWire
- 20 days ago - Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor - GlobeNewsWire
- 2 months ago - Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F - GlobeNewsWire
- 2 months ago - Inventiva announces the nomination of Andre Turenne as Director - GlobeNewsWire
- 2 months ago - Inventiva reports its 2023 full-year results - GlobeNewsWire